eurotimes.org
EUROTIMES STORIES

Marketing authorisation

European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Roclanda®

Colin Kerr

Posted: Monday, February 1, 2021

Aerie Pharmaceuticals has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%.
“We are delighted that the CHMP has adopted a positive opinion for Roclanda®,” said Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer at Aerie.
Roclanda is currently marketed as Rocklatan® in the United States and is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or hypertension.
www.aeriepharma.com


Latest Articles


escrs members advert